Recent studies with hepatoma cells have shown that imatinib inhibits c-Abl cytosolic tyrosine kinase to attenuate insulin-induced but not IGF-1-induced phosphorylation of Akt and GSK-3β [26]. Here, ABL1 is linked to hepatocellular carcinoma.